Illumina (NASDAQ:ILMN) Shares Gap Down – Time to Sell?

Illumina, Inc. (NASDAQ:ILMN)’s stock price gapped down before the market opened on Friday. The stock had previously closed at $290.06, but opened at $255.77. Illumina shares last traded at $251.6740, with a volume of 591,460 shares.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported third-quarter adjusted earnings of $1.44 per share, above the $1.36 analyst consensus and up from $1.34 a year earlier. Illumina Q3 Earnings Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance, citing strong clinical sequencing demand and continued adoption of the NovaSeq X platform. These trends support expectations for improved growth in clinical markets, even as research-related demand remains softer. ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
• Positive Sentiment: Longer term, Illumina remains positioned in expanding genomics markets, including clinical sequencing, population screening, metagenomics and precision medicine. 3 Promising Genomics Stocks to Add to Your Portfolio Now
• Neutral Sentiment: JPMorgan reduced its price target to $300 from $320, signaling somewhat lower near-term expectations while maintaining a target above recent trading levels. JPMorgan Adjusts Price Target on Illumina
• Negative Sentiment: Third-quarter revenue increased 4.2% year over year to approximately $1.13 billion but fell short of Wall Street expectations. Investors also reacted negatively to ongoing China revenue pressures, softer research demand and pricing pressure. Illumina Shares Tumble Despite Earnings Beat on China Woes

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ILMN. Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Piper Sandler raised their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Finally, Guggenheim lifted their target price on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $234.41.

Illumina Stock Performance

The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a fifty day moving average price of $248.84 and a two-hundred day moving average price of $175.73. The company has a market cap of $35.94 billion, a P/E ratio of 44.50, a PEG ratio of 4.09 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company posted $1.34 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,061,235 shares of company stock worth $436,356,102 over the last 90 days. 2.90% of the stock is owned by insiders.

Institutional Trading of Illumina

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC grew its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA acquired a new position in shares of Illumina in the 2nd quarter worth approximately $617,981,000. Janus Henderson Group PLC raised its holdings in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after purchasing an additional 29,094 shares in the last quarter. Finally, Southpoint Capital Advisors LP raised its holdings in shares of Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock worth $258,846,000 after purchasing an additional 349,536 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.